Citations

Clear

409 citation(s) found for "Rivera, A".

Building Anatomical Knowledge Competency for PGY‐1 Readiness: Design, Implementation and Learner's Perception of A Year 4 Clinical Anatomy Elective
Salinas-Alvarez, Yolanda , Rivera-Perez, Juan Antonio , Forston, Morgan J , Lachman, Nirusha

Mayo Clinic

Clinical Anatomy | October 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ca.70239 | PMID 42847240 Get It

ABSTRACT Persistent gaps in anatomical knowledge among incoming residents have raised concerns about clinical preparedness, especially in surgical and interventional disciplines. Conventional anatomy instruction and limited cadaveric exposure and learning opportunities in medical curricula have prompted calls for innovative, clinically focused anatomical curricular integration in clinical training. This article describes the development, implementation, and impact of a tailored Year 4 Clinical Anatomy Elective in the Department of Clinical Anatomy at Mayo Clinic, designed to reinforce competency in clinically relevant anatomical understanding and support learners' perceived preparedness during transitions to residency. A 4‐week elective was designed for fourth‐year medical students interested in pursuing a specific residency program. The course was personalized for students' clinical interests and incorporated fresh tissue dissection, simulation, procedural skills training, and imaging using an immersive learning platform. The elective was structured within the experiential learning model using a guided, self‐directed format within a multicapability laboratory and instructional environment, grounded in constructivist theory. A 5‐year review of elective records and informal thematic analysis of student feedback were conducted. Most participants pursued surgically related specialties, with orthopedic surgery being the most common. Exploratory thematic analysis identified six core themes: Professional Identity Formation, Educational Benefits, Learning Challenges, Connection to Clinical Practice, Patient Care Implications, and Future Preparation and Transferability. These students perceived gains in areas aligned with ACGME milestones: increased confidence, greater preparedness for residency, and improvement in their ability to apply anatomical knowledge in clinical settings. This perception may be indicative of lifelong learning and early educator identity formation. A specialty‐specific, clinically integrated anatomy elective may support learners' perceived preparedness for residency, reinforce clinically relevant anatomical understanding, and support the development of educational and professional competencies. Such targeted interventions may help address perceived gaps in anatomical preparedness during the transition to residency and contribute to postgraduate training within a competency‐based medical education framework.
Integration of cadaveric dissections with emerging digital technologies in a neurosurgery and neuroanatomy residency training program: Implementation and first‐year experience
Bauman, Megan , Kattil, Punnose K , Leonel, Luciano César Pereira Campos , Forston, Morgan J , Salinas-Alvarez, Yolanda , Rivera-Perez, Juan Antonio , Graepel, Stephen , Lachman, Nirusha , Peris-Celda, Maria

Mayo Clinic

Anatomical Sciences Education | September 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ase.70345 | PMID 42791609 Get It

Abstract Neuroanatomy remains a core competency in neurosurgical training, particularly in skull base education, where learners must integrate three‐dimensional spatial understanding, radiologic correlation, and stepwise procedural knowledge. Cadaveric dissection remains foundational, but adjunctive digital tools may strengthen repeated visualization and anatomical review. We describe the educational rationale and implementation of integrating stereoscopic teaching, a stepwise digital application, photogrammetry, and virtual reality within an established neurosurgical skull base curriculum. Within the Mayo Clinic cranial base course embedded in a broader longitudinal curriculum, four postgraduate year 4 neurosurgery residents participated in transcranial and endoscopic cadaveric dissections supported by stereoscopic lectures, workstation‐based tablet guidance, and immersive review using photogrammetry, virtual reality, and computed tomography/magnetic resonance imaging correlation. The integrated design aligned these modalities with course objectives in anatomical landmark recognition, operative corridor planning, radiologic‐anatomic translation, and stepwise procedural rehearsal. The educational contribution of this model lies in the intentional integration of digital adjuncts around cadaveric dissection rather than in a single technology alone. This multimodal sequence may support spatial understanding, procedural preparation, and competency‐oriented skull base training while extending review beyond the laboratory. Current evaluation is best interpreted as preliminary program evaluation rather than definitive learner‐outcome evidence. This model may offer a transferable approach for programs seeking to complement cadaveric education with emerging digital tools and provides a basis for future prospective evaluations using multiple low‐stakes assessment data points across the broader curriculum.
Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta‐Analysis of Randomized Controlled Trials
Mansouri, Ensieh S. , Queiroga, Flavia , Barbosa, Lucas , Azevedo, Anne K. , Donaldy, Webster , Mirbolouk, Mohammad Jafar, Blair, Camila V. , Rivera, André , Félix, Iuri Ferreira , Abreu, Marconi , Deshmukh, Abhishek , Barbosa, Lucas Mendes , Ferreira Felix, Iuri , Deshmukh, Abhishek J , DeSimone, Christopher V , Queiroga, Flavia Firmino de , Azevedo, A K , Mirbolouk, M J, DeSimone, Christopher V. , Rivera, A

Mayo Clinic

Journal of the American Heart Association | September 9, 2026 | Volume: 15 | Issue: 18 | Pages: No page available

10.1161/jaha.125.044249 | PMID 42714458 Get It

Background Tirzepatide is a dual agonist for glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptors, with proven efficacy in weight loss and improvement in cardiovascular outcomes. However, the effects of tirzepatide on the incidence of atrial fibrillation in patients with overweight or obesity remain unclear. Methods PubMed, Embase, and Cochrane Library were searched for randomized controlled trials comparing tirzepatide versus placebo for individuals with overweight or obesity. Odds ratios (ORs) with 95% credible intervals (CrIs) were pooled using a Bayesian binomial‐normal hierarchical model, appropriate for rare‐event outcomes. Results Our meta‐analysis included 10 randomized controlled trials, including 6515 individuals, of whom 4491 (68.9%) were randomized to tirzepatide. The pooled OR was 2.20 (95% CrI, 0.81–6.75) for atrial fibrillation, 2.16 (95% CrI, 0.90–5.87) for atrial arrhythmia, and 1.84 (95% CrI, 1.04–3.90) for any arrhythmia. Conclusions Tirzepatide was not associated with atrial fibrillation or atrial arrhythmia. Although higher odds of overall arrhythmias were observed, event rates were low and the findings should be interpreted cautiously.
Cardiometabolic and ASCVD Outcomes Associated with Tirzepatide: Insights from a One-Year Multicenter Observational Study
Castaneda, Regina , Verastegui, Alfredo , Ghusn, Wissam , Bechenati, Dima , Espinosa, Maria A , Villamarin, Jose L. , Tama, Elif , Frederiksen, Kirsten , Acosta, Andrés , Ghusn, Wissam , Bechenati, Dima , Acosta, Andres , Villamarin, Jose , Verastegui, Alfredo , Tama, Elif , Castaneda, Regina , Gutiérrez, René de Jesús Rivera , Hurtado, Maria D. , Rivera Gutierrez, Rene de J , Espinosa, Maria A , Frederiksen, Kirsten , Hurtado, Maria Daniela

Mayo Clinic

Journal of the Endocrine Society | September 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1210/jendso/bvag210 | PMID 42812847 Get It

Abstract Purpose To evaluate the association of long-term, continuous tirzepatide use with cardiometabolic risk parameters and estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk in real-world practice. Methods This multicenter retrospective observational study included 1,028 adults with overweight or obesity who received weekly subcutaneous tirzepatide for at least 12 months within the Mayo Clinic Health System from June 2022 through May 2024. ASCVD risk analyses included 275 individuals with complete baseline and 12-month follow-up data. Outcomes were changes in cardiometabolic parameters, estimated 10-year ASCVD risk, and ASCVD risk category. Results At 12 months, median total body weight loss (TBWL) was 12.6%. Fasting glucose, HbA1c, triglycerides, and alanine aminotransferase decreased by 19.5%, 16.0%, 8.5%, and 10.6%, respectively, whereas HDL cholesterol increased by 11.3% (all P < .001). Mean 10-year ASCVD risk did not change significantly overall (mean relative change, −3.7%; P = .18), but changes differed by TBWL category (ANOVA, P < .001). ASCVD risk decreased among individuals achieving 10%–20% TBWL (−9.6%; P = .009) and >20% TBWL (−14.2%; P = .005), but not among those achieving <10% TBWL (+7.7%; P = .22). Low-risk prevalence increased from 38.3% to 46.4% (P < .001), with 11.7% transitioning from higher-risk categories to low risk. Main findings Continuous tirzepatide use for at least 12 months was associated with clinically meaningful improvements in cardiometabolic parameters. Reductions in estimated 10-year ASCVD risk were observed among individuals achieving at least 10% TBWL, supporting greater weight loss as an important marker of cardiovascular risk improvement.
Practice Variation in Antibiotic Duration for Acute Otitis Media in Children Aged 2 to 5 Years
Rivera-Sepúlveda, Andrea , Mohammad, Nabeel , Okocha, Adaobi, Li, Zhuo, Blumenfeld, Sophia, Zomorrodi, Arezoo , Li, Zhuo

Mayo Clinic

Pediatric Emergency Care | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/pec.0000000000003670 | PMID 42552999 Get It

Background: Acute otitis media (AOM) is among the most common pediatric infections and a leading indication for antibiotic prescribing. Although current guidelines recommend 5 to 7 days of therapy for children 2 to 5 years of age with uncomplicated AOM, variation in antibiotic duration remains common. We evaluated whether a 5-day antibiotic course was associated with similar short-term outcomes compared with a 7-day course. Methods: We conducted a retrospective multicenter cohort study using electronic health record data from 44 pediatric emergency departments, urgent care centers, and primary care practices within an integrated health care system. Children 2 to 5 years of age with uncomplicated AOM treated with a single oral antibiotic during 2022 were included. The primary analysis compared children prescribed 5 versus 7 days of therapy. Treatment failure was defined as an AOM-related return encounter requiring a new systemic antibiotic prescription within 7 days after completion of therapy (EOT+7). Secondary analyses evaluated outcomes by antibiotic class and prespecified sensitivity analyses. Results: The final analytic cohort included 7528 children; 906 received 5-day therapy, and 1799 received 7-day therapy. Treatment failure occurred in 0.44% and 0.61%, respectively (absolute risk difference: −0.17%; 95% CI: −0.73 to 0.39; risk ratio: 0.72; 95% CI: 0.23-2.26). Findings were consistent across antibiotic-specific and sensitivity analyses. Conclusions: Among children 2 to 5 years of age with uncomplicated AOM, a 5-day antibiotic course was not associated with an increased risk of short-term treatment failure compared with a 7-day course, supporting guideline-concordant prescribing and outpatient antimicrobial stewardship.
Pediatric sarcomas: challenges and opportunities
Gao, Yuan, Bailey, Kelly M. , Blackman, Samuel C. , Bushweller, John H. , Chong, Shasha , DeHond, Kevin, Grembecka, Jolanta , Hatley, Mark E. , Kadoch, Cigall , Koehler, Angela N. , Linardic, Corinne M. , Renna, Phil, Stewart, Elizabeth A., Stillman, Bruce , Sweet-Cordero, E. Alejandro, Reu, Frederic J , Stillman, Bruce , Stegmaier, Kimberly , Vakoc, Christopher R , Guenther, Lillian M , Reu, Frederic J. , Rivera, Miguel N. , Stewart, Elizabeth A. , Sweet-Cordero, Alejandro

Mayo Clinic

Genes & Development | August 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/gad.353549.125 | PMID 42552078 Get It

Pediatric sarcomas are a heterogeneous group of rare mesodermal malignancies. These cancers, which affect children from infancy through adolescence and young adulthood, are in general challenging to treat with currently available therapies. Biologically, many are characterized by quiet genomes, fusion oncoproteins, immune “cold” microenvironments, and vast epigenetic deregulation that contributes to diverse and complex mechanistic drivers. Multifaceted advancements in research strategies, including high-throughput screening, new model systems, surfaceome profiling, and study of oncogenic fusion condensates have led to new opportunities for understanding the biology of pediatric sarcomas. To continue to make progress for these difficult to treat cancers, it will be critical to continue to improve access to bioinformatic data, approach patient care using innovative clinical trial frameworks, and foster interdisciplinary partnerships among medicinal chemists, scientists, clinicians, advocates, and industry partners.
TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo
Jalali, Shahrzad , Natesampillai, Sekar, Nie, Zilin , Zhang, Ying, Chandrasekar, Aswath P. , Hameister, Brianna M., Correia, Cristina, Mun, Dong-Gi, Garcia-Rivera, Enrique, Matson, Robert , Krogman, Ashton, Maynes, Mark A., Batchelor, Robin, Monie, Dileep D. , Behfar, Atta, Ansell, Stephen M. , Taner, Timucin, Weyand, Cornelia, Billadeau, Daniel D. , Garcia-Rivera, Enrique , Zhao, Tuantuan V, Garcia-Rivera, Enrique , Monie, Dileep D , Can, İsmail , Correia, Cristina , Zhao, Tuantuan V. , Mun, Dong‐Gi , Krogman, Ashton , Maynes, Mark A , Li, Hu , Behfar, Atta , Kenderian, Saad S. , Pandey, Akhilesh , Taner, Timuçin , Weyand, Cornelia M. , Badley, Andrew D.

Mayo Clinic

Journal of Clinical Investigation | August 2, 2026 | Volume: 136 | Issue: 15 | Pages: No page available

10.1172/jci194449 | PMID 42544577 Get It

TRAIL is a TNF family ligand that trimerizes TRAIL-R1 (DR4) or TRAIL-R2 (DR5) to induce apoptosis, necroptosis, and/or NF-κB activation in receptor-bearing cells. We previously identified TRAILshort as a splice variant of TRAIL that lacks cysteine 230, cannot trimerize, and acts as a dominant-negative ligand that blocks TRAIL-mediated apoptosis. TRAILshort is expressed on cell surfaces and within extracellular vesicles, enabling it to confer TRAIL resistance to both producing and bystander cells. In this study, we showed that elevated TRAILshort levels were associated with chronic viral infections, cancer, and autoimmune diseases, suggesting a link to impaired immune regulation. Using unbiased phosphoproteomics and mechanistic studies, we demonstrated that TRAILshort binding to DR5 recruited and activated the phosphatase Src homology region 2 domain–containing phosphatase 1 (SHP-1), leading to zeta-chain-associated protein kinase 70 (ZAP-70) dephosphorylation, disruption of ZAP-70–CD3ζ interactions, and impaired T cell receptor signaling, thereby reducing T cell activation, proliferation, and cytokine production in response to antigen or CD3/CD28 ligation. Genetic or pharmacologic SHP-1 inhibition reverses these effects. In humanized mouse models, TRAILshort promoted the persistence of transformed mouse embryonic fibroblasts (MEFs) and L428 and antagonized CD19-directed CAR T cell activity, revealing TRAILshort as an immunomodulator of T cell function with therapeutic implications, including blocking TRAILshort to restore T cell immunity or delivering TRAILshort to enforce tolerance. TRAILshort, a variant of TRAIL, suppresses T cell function and immune responses in cancer and infectious diseases, highlighting its potential as a therapeutic target.
Impact of community-led cancer advocacy program on cancer health outreach and research navigation among immigrants of African descent
Bolajoko, Opeyemi O., Ramirez-Rivera, Caleb O. , Bolajoko, Olasanmi S., Stephenson, Noreen A., Gordon, Vinessa, Aliche, Obianuju, Odedina, Folakemi T., Gordon, Vinessa A, Bolajoko, Opeyemi , Aliche, Obianuju

Mayo Clinic

Frontiers in Health Services | July 29, 2026 | Volume: 6 | Issue: No issue available | Pages: No page available

10.3389/frhs.2026.1820297 | PMID 42591091 Get It

Introduction Immigrants of African Descent (IAD) are a subset of the population in the United States with unique healthcare needs and experiences driving health disparities, including inadequate access to healthcare for cancer prevention and control. This study reports the impact of a Cancer advocacy program in IAD communities, using the training of trainers approach. Methods IAD from different organizations were invited to undergo cancer advocacy training organized by Inclusive Cancer Care Research Equity and Mayo Clinic Comprehensive Cancer Center as Master trainers on colorectal, breast, and prostate cancers. Participation was through in-person training and Zoom sessions. Our team communicated with participants frequently via email to provide support and updates. The Master trainers led cancer awareness programs within their communities during the second phase of the program. Results Participants included two breast cancer survivors, three prostate cancer survivors, six cancer caregivers, and 19 community advocates. There were 19 advocate-led cancer risk reduction and research participation events, reaching 2045 community members, and 875 were navigated to research. Community responses showed that 96% found the information given at the Master Trainer-led event was very useful, 46% promised to seek more cancer information, and 17% agreed to volunteer to become a cancer advocate. The insights from this study suggested that the train-the-trainers’ approach was efficient in ensuring community ownership of cancer advocacy. Conclusion IAD can be trained to effectively lead advocacy programs in immigrant communities, using the train-the-trainer approach. Future studies should establish the feasibility of sustaining community outreach and research navigation in IAD communities to improve cancer prevention and cancer care outcomes in this population.
Cross-scale echoes of ultrafast oscillations in the human brain
Anonymous , Trávníček, Vojtěch , Rivera, Luis Felipe Sarmiento , Worrell, Gregory, Kucewicz, Michał T. , Brázdil, Milan, Kucewicz, Michal , Worrell, Gregory A. , Brázdil, Milan

Mayo Clinic

Physical Review E | July 28, 2026 | Volume: 114 | Issue: 2 | Pages: No page available

10.1103/jjzp-h5qf | PMID 42768526 Get It

Ultrafast oscillations (UFOs) are brief bursts of high-frequency (2–8 kHz) activity recorded using depth electrodes in epileptic brain tissue. While reliably detected at small scales using microelectrodes, UFOs have thus far likely not been observed at larger scales using macroelectrodes. Here we show that faint echoes of these bursting patterns can be detected in macroelectrode signals using a model of cross-scale propagation. To model this cross-scale effect, we extend the classical damped wave equation to include an explicit scale coordinate governed by the dilation operator. We then use Green's functions to obtain an expression for the spectral echo expected at the macroelectrode scale. This echo takes the form of a carrier envelope modulated by the temporal structure of the original microscale bursting event. We test the predicted signature echo pattern in human intracranial recordings from eleven epilepsy patients implanted with both micro- and macroelectrodes. Statistically significant echoes are confirmed in two out of eleven patients, appearing in 2% of all tested micro-macro pairs.
A Retrospective Analysis of Itraconazole and Hydroxy-Itraconazole Serum Concentrations Correlation to Clinical Outcomes of Histoplasmosis Treatment
Firkus, Danielle , Stevens, Ryan W., Saleh, Omar Abu , Cole, Kristin, Enzler, Mark J., Haan, Meghan , HERGES, JOSEPH, Jannetto, Paul J. , Vergidis, Paschalis, Rivera, Christina G. , Abu Saleh, Omar M, Rivera, Christina G , Stevens, Ryan W. , Herges, Joseph R. , Vergidis, Paschalis

Mayo Clinic

Therapeutic Drug Monitoring | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ftd.0000000000001513 | PMID 42519926 Get It

Background: Itraconazole is the preferred antifungal agent for mild to moderate histoplasmosis and step-down therapy following amphotericin B treatment. Although hydroxy-itraconazole, a major metabolite of itraconazole, displays antifungal activity comparable with that of the parent compound, its role in therapeutic drug monitoring targets for histoplasmosis remains uncertain. Methods: The objective was to compare clinical outcomes and adverse events using itraconazole parent-compound concentrations alone versus combined itraconazole and hydroxy-itraconazole concentrations in patients treated for histoplasmosis. This retrospective cohort study included adults with probable or proven histoplasmosis who received itraconazole and had at least 1 documented serum concentration. The primary outcome was clinical response across 3 groups: (1) parent (itraconazole parent-compound concentration >1.0 mcg/mL), (2) combined (parent-compound concentration <1.0 mcg/mL with combined itraconazole plus hydroxy-itraconazole >1.0 mcg/mL), and (3) subtherapeutic (failure to reach either threshold). Treatment response and adverse events were analyzed using the Fisher exact test. Results: Among 108 patients (parent, n = 40; combined, n = 40; subtherapeutic, n = 28), response rates differed across groups (parent (95%); combined (90%); subtherapeutic (67.9%); P = 0.006). There was no difference between the parent and combined groups. Adverse events did not differ, although drug discontinuation occurred more frequently in the subtherapeutic group (parent (5%); combined (20%); subtherapeutic (25%); P = 0.04). Conclusions: Patients who failed to achieve either an itraconazole concentration >1 mcg/mL or a combined itraconazole plus hydroxy-itraconazole concentration >1 mcg/mL had lower response rates. Similar outcomes among patients achieving the itraconazole target alone and those achieving the combined target suggest that hydroxy-itraconazole concentrations may contribute to therapeutic drug monitoring targets in histoplasmosis.